profit from every $100 of sales.
$0$100
bioAffinity Technologies
$2.20-5.98% today
-96.1% in 1 year
1-year low $2.201-year high $71.10
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What bioAffinity Technologies sold, what it kept, and what it did with the cash.
Sales went from $4,803 in 2022 to $6.11 million in 2025, with -$14.9 million of profit last year.
SalesProfit
bioAffinity Technologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| bioAffinity Technologies | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads bioAffinity Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 3 | 9 | 6 | |
| 0 | 1 | 3 | 2 | |
| -4 | -8 | -9 | -11 | |
| -6 | -8 | -8 | -14 | |
| -8 | -8 | -9 | -15 | |
| -54.30 | -27.30 | -22.50 | -8.66 | |
| 90.3% | 31.3% | 36.1% | 30.8% | |
| -83,511.5% | -314.8% | -95.6% | -174.0% | |
| -169,771.2% | -313.4% | -96.6% | -244.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 12 | 8 | 7 | 11 |
| Cash | 11 | 3 | 1 | 6 |
| Total debt | 0 | 2 | 2 | 1 |
| Total liabilities | 1 | 3 | 4 | 4 |
| 11 | 5 | 3 | 7 | |
| 0 | 0 | 0 | 2 | |
| -39.3% | -96.7% | -172.0% | -138.8% | |
| -73.8% | -163.5% | -347.4% | -204.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -6 | -7 | -9 | |
| 0 | 0 | 0 | 0 | |
| -4 | -6 | -7 | -9 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 2.5×
- 0.7×
- –
- –
- -234.5%
- -372.4%
- 0.0%
Profitability
- 30.8%
- -174.0%
- -244.1%
- -271.3%
- -229.2%
- -89.9%
- -358.8%
- -199.9%
- -242.9%
- 34.2%
Growth
- +983.4%
- –
- −27.9%
- –
- +109.5%
Financial health
- -0.4×
- 0.38
- 17.4%
- -816.3×
- 1.36
- 1.34
- 0.71
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 872
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -0.81 | -2.40 | +66.3% |
| Mar 13, 2026 | -1.11 | -2.70 | +58.9% |
| Nov 14, 2025 | -2.70 | -2.70 | +0.0% |
| Aug 14, 2025 | -3.90 | -2.70 | −44.4% |
| May 15, 2025 | -0.16 | -0.16 | +0.0% |
| Mar 31, 2025 | -0.21 | -0.14 | −50.0% |
| Nov 14, 2024 | -0.16 | -0.15 | −6.7% |
| Aug 14, 2024 | -0.19 | -0.17 | −11.8% |
News
bioAffinity Technologies GAAP EPS of -$5.89, revenue of $1.1MSeeking Alpha · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
33No pass
Philip Fisher
39No pass
Peter Lynch
44No pass
Joel Greenblatt
–Not enough data
Charlie Munger
26No pass
Terry Smith
24No pass
Questions about bioAffinity Technologies
Is bioAffinity Technologies a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the bioAffinity Technologies AI analysis
What does bioAffinity Technologies do?
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It is in Medical - Diagnostics & Research.
Does bioAffinity Technologies pay a dividend?
No. bioAffinity Technologies does not pay a dividend at the moment.
Is bioAffinity Technologies stock halal?
No. bioAffinity Technologies does not pass our halal screen: its cash and confirmed interest-bearing investments are 161% of its market value, at or above the 33% limit. How we check
How has bioAffinity Technologies stock done over the past year?
Down 96.1% over the past twelve months, to $2.20. It traded between $2.20 and $71.10 and is 96.9% below its high.
Who are bioAffinity Technologies's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with bioAffinity Technologies's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.